Floatz logo

Pembrolizumab

Decompensated Cirrhosis

Genfitmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Decompensated Cirrhosis cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Institute of Liver and Biliary Sciences, India
Phase 3BB
Avatrombopag
Tongji Hospital
Phase 4BB
L-Ornithine-L-Aspartate
Air Force Military Medical University, China
Phase 2/3B
BIV201
BioVie Inc.
Phase 2CCC
Carboplatin
Genfit
Phase 2CCC

View all 12 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →